Home UPDATE 2-AbbVie oral hep C drugs cure 96 pct in late stage trial
 

Keywords :   


UPDATE 2-AbbVie oral hep C drugs cure 96 pct in late stage trial

2013-12-11 01:07:56| Biotech - Topix.net

AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive race to deliver new treatments for the serious liver disease.

Tags: update late stage trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Atlantic Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
More »